Mahata Manjula, Mahapatra Nitish R, O'Connor Daniel T, Mahata Sushil K
Department of Medicine and Center for Molecular Genetics, University of California, San Diego, La Jolla, California 92093-0838, USA.
Mol Pharmacol. 2002 Jun;61(6):1340-7. doi: 10.1124/mol.61.6.1340.
Activation of protein kinase C (PKC) stimulates nicotine-induced catecholamine secretion. PKC down-regulation by prolonged pretreatment with phorbol 12-myristate 13-acetate diminished nicotine-induced catecholamine secretion only slightly (approximately 16%), suggesting substantial PKC independence of nicotinic receptor activation. However, we found that bisindolylmaleimide compounds (which are also putative PKC chemical inhibitors) dramatically inhibited nicotine-induced catecholamine secretion (IC(50) values of approximately 24-37 nM). This inhibition was specific for the nicotinic cholinergic receptor. Catecholamine secretion induced by other nicotinic agonists (such as epibatidine, anatoxin, or cytisine) was also powerfully antagonized by bisindolylmaleimide II (IC(50) values of approximately 60-90 nM). Even high-dose nicotinic agonists failed to overcome the inhibition by bisindolylmaleimide II, suggesting noncompetitive nicotinic antagonism by this class of compounds. Nicotinic inhibition by bisindolylmaleimide seemed not to be readily reversible. Structure-activity studies of bisindolylmaleimide compounds revealed that bisindolylmaleimides I through III are the most potent nicotinic antagonists at the nicotinic cholinergic receptor in PC-12 cells (IC(50) < or =37 nM), whereas bisindolylmaleimide IV and V have far less nicotinic antagonist activity (IC(50) >1 microM); the active compounds I through III have cationic tails at an indole nitrogen, whereas the least potent compounds IV and V do not. By contrast, a free NH within the maleimide ring is crucial for PKC inhibition by this class of compounds. We conclude that bisindolylmaleimides I through III are some of the most potent noncompetitive neuronal nicotinic antagonists, indeed the most potent such antagonists we have observed in PC-12 cells. Nicotinic antagonism of these compounds seems to be independent of PKC inhibition.
蛋白激酶C(PKC)的激活会刺激尼古丁诱导的儿茶酚胺分泌。用佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯进行长时间预处理使PKC下调,仅轻微减少了尼古丁诱导的儿茶酚胺分泌(约16%),这表明烟碱受体激活在很大程度上不依赖PKC。然而,我们发现双吲哚马来酰亚胺化合物(它们也是假定的PKC化学抑制剂)显著抑制尼古丁诱导的儿茶酚胺分泌(IC50值约为24 - 37 nM)。这种抑制对烟碱型胆碱能受体具有特异性。双吲哚马来酰亚胺II也强烈拮抗其他烟碱激动剂(如依博碱、anatoxin或金雀花碱)诱导的儿茶酚胺分泌(IC50值约为60 - 90 nM)。即使是高剂量的烟碱激动剂也无法克服双吲哚马来酰亚胺II的抑制作用,这表明这类化合物具有非竞争性烟碱拮抗作用。双吲哚马来酰亚胺引起的烟碱抑制似乎不易逆转。双吲哚马来酰亚胺化合物的构效关系研究表明,双吲哚马来酰亚胺I至III是PC - 12细胞烟碱型胆碱能受体上最有效的烟碱拮抗剂(IC50≤37 nM),而双吲哚马来酰亚胺IV和V的烟碱拮抗活性则低得多(IC50>1 μM);活性化合物I至III在吲哚氮上有阳离子尾巴,而活性最低的化合物IV和V则没有。相比之下,马来酰亚胺环内的游离NH对于这类化合物抑制PKC至关重要。我们得出结论,双吲哚马来酰亚胺I至III是一些最有效的非竞争性神经元烟碱拮抗剂,实际上是我们在PC - 12细胞中观察到的最有效的此类拮抗剂。这些化合物的烟碱拮抗作用似乎与PKC抑制无关。